Exactech Shares Industry’s First Shoulder Replacement Surgery “Smart Score” Metric Based on Machine Learning

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today the first orthopaedic clinical outcomes measure based on machine learning.

The Shoulder Arthroplasty Smart (SAS, or “Smart”) Score quantifies clinical outcomes for shoulder arthroplasty patients so surgeons can determine how well patients are doing before and after surgery. The score is available to any surgeon or researcher through the website.

Unlike existing scores available in the industry, the Smart Score offers surgeons a more efficient means of measuring patient outcomes by requiring only half the inputs of other scores. With just six patient-specific inputs, determined through machine learning research to be the most significant assessments of post-operative outcomes, the Smart Score (ranging from 0-100) is determined for each patient.

The score is based on three objective active range of motion measures and three subjective measures of the patient’s pain and function. The Smart Score will be used as part of Exactech’s new Predict+™ clinical decision support tool that uses machine learning to provide predictions of individual patient outcomes after shoulder replacement surgery.

A paper recently published in JSES Seminars in Arthroplasty concluded that machine learning can help create more efficient and effective clinical outcome measures. Another paper published this week in the Journal of Shoulder and Elbow Surgery compared the new Smart Score to five other assessment tools currently available and found that it was more efficient, with fewer inputs, and showed equivalent or better validity, responsiveness and clinical interpretability.

“Historically, there has not been a single gold standard tool to quantify outcomes before and after shoulder replacement surgery,” said orthopaedic surgeon Joseph Zuckerman, MD, of NYU Langone Orthopedic Hospital, and an Equinoxe® shoulder replacement system design team surgeon. “Because of that, shoulder surgeons have used many different generic shoulder outcome scores to quantify pain relief or functional improvement after shoulder arthroplasty. Our clinical research detailed in this publication proposed a new shoulder arthroplasty-specific clinical outcome score, the Shoulder Arthroplasty Smart Score, that more accurately and efficiently quantifies outcomes, without the bias, ceiling effects or response range issues of the other scores.”

Exactech Vice President of Extremities Chris Roche added, “Three of the most common tools to quantify clinical outcomes in the shoulder are the ASES, Constant and UCLA scores. These tools were developed 30 years ago and have changed little since that time despite significant advances in treatment and data science. New machine learning-based analyses provide an opportunity to evaluate the predictive validity of these historical tools.

He concluded, “In fact, our research identified the preoperative input questions that are predictive of clinical outcomes, and those that aren’t predictive. We also found that the majority of the inputs composing these three historical clinical tools were of low predictive validity, suggesting the need for an altogether new tool like the Smart Score, with preoperative inputs that are more correlated to post-operative outcomes after shoulder surgery.”

SourceExactech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version